Loading...
•
Sep 30
Alkermes Q3 2025 Earnings Report
Alkermes reported strong third quarter 2025 financial results with increased revenues and profitability, and raised its full-year financial expectations.
Key Takeaways
Alkermes plc delivered a successful third quarter in 2025, marked by strong revenue growth and robust profitability, driven by solid performance across its commercial portfolio. The company reported total revenues of $394.2 million and GAAP net income of $82.8 million, with diluted GAAP earnings per share of $0.49. Alkermes also ended the quarter in a strong financial position with $1.14 billion in cash, cash equivalents, and total investments, and subsequently raised its financial outlook for the full year 2025.
Total revenues for the third quarter of 2025 reached $394.2 million, demonstrating strong growth compared to the previous year.
GAAP Net Income for the quarter was $82.8 million, resulting in diluted GAAP earnings per share of $0.49.
The company's proprietary net sales, including VIVITROL, ARISTADA, and LYBALVI, showed significant increases, contributing to overall revenue growth.
Alkermes raised its full-year 2025 financial expectations, reflecting confidence in continued business momentum and future performance.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Net Sales Revenue
CapyFin.comARISTADA Net Sales Revenue
CapyFin.comLYBALVI Net Sales Revenue
CapyFin.comVUMERITY Mfg & Royalty Revenue
CapyFin.comOther Mfg & Royalty Revenue
CapyFin.com Forward Guidance
Alkermes raised its financial expectations for the full year 2025, anticipating higher total revenues, increased net sales for key proprietary products, and improved profitability metrics such as GAAP Net Income, EBITDA, and Adjusted EBITDA.
Positive Outlook
- Total Revenues are expected to be between $1,430 million and $1,490 million, an increase from previous guidance.
- VIVITROL Net Sales guidance raised to $460 million – $470 million.
- ARISTADA Net Sales guidance raised to $360 million – $370 million.
- LYBALVI Net Sales guidance raised to $340 million – $350 million.
- GAAP Net Income guidance increased to $230 million – $250 million.
- EBITDA guidance raised to $270 million – $290 million.
- Adjusted EBITDA guidance raised to $365 million – $385 million.
Challenges Ahead
- Cost of Goods Sold guidance slightly increased to $195 million – $205 million.
- R&D Expense guidance slightly increased to $315 million – $325 million.
- SG&A Expense guidance slightly increased to $675 million – $705 million.
- The proposed acquisition of Avadel Pharmaceuticals introduces integration risks and potential litigation.
- Forward-looking statements are subject to inherent uncertainties and risks, and actual results may differ materially.
Revenue & Expenses
Visualization of income flow from segment revenue to net income